Business Description
Immuneering Corp
NAICS : 325412
SIC : 2834
ISIN : US45254E1073
Share Class Description:
IMRX: Class ATotal Employee Number:
55Description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 42.01 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.7 | |||||
3-Year EPS without NRI Growth Rate | 12.7 | |||||
3-Year FCF Growth Rate | 15.3 | |||||
3-Year Book Growth Rate | -6.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -9.73 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.47 | |||||
9-Day RSI | 59.68 | |||||
14-Day RSI | 57.62 | |||||
3-1 Month Momentum % | -22.55 | |||||
6-1 Month Momentum % | -5.42 | |||||
12-1 Month Momentum % | 0.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 32.45 | |||||
Quick Ratio | 32.45 | |||||
Cash Ratio | 31.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.8 | |||||
Shareholder Yield % | -64.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -37.61 | |||||
ROA % | -34.96 | |||||
ROIC % | -185.75 | |||||
3-Year ROIIC % | -17.74 | |||||
ROC (Joel Greenblatt) % | -1347.22 | |||||
ROCE % | -39.94 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.63 | |||||
Price-to-Tangible-Book | 1.7 | |||||
EV-to-EBIT | -3.11 | |||||
EV-to-EBITDA | -3.13 | |||||
EV-to-Forward-EBITDA | 130.22 | |||||
EV-to-Forward-Revenue | 733.06 | |||||
EV-to-FCF | -3.69 | |||||
| Price-to-Net-Current-Asset-Value | 2.21 | |||||
| Price-to-Net-Cash | 2.28 | |||||
Earnings Yield (Greenblatt) % | -32.15 | |||||
FCF Yield % | -14.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immuneering Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.17 | ||
| Beta | 2.5761 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | 82.36 | ||
| 14-Day RSI | 57.62 | ||
| 14-Day ATR ($) | 0.315811 | ||
| 20-Day SMA ($) | 4.8445 | ||
| 12-1 Month Momentum % | 0.48 | ||
| 52-Week Range ($) | 2.9 - 10.08 | ||
| Shares Outstanding (Mil) | 64.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immuneering Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immuneering Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 29 days | ||
| General meeting for 2026 | 2026-06-11 11:00 | 3.92 (-1.75%) | ||
| Atebimetinib ASCO Data Update in 1L Pancreatic Cancer | 2026-06-01 08:00 | 5.78 (+11.80%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 5.14 (-4.10%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 15:45 | 5.52 (-1.95%) | ||
| the Leerink Global Healthcare Conference | 2026-03-09 15:40 | 5.33 (+9.90%) | ||
| Annual report for 2025 | 2026-03-06 | 4.98 (-2.35%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-06 | 4.98 (-2.35%) |
Show
Entries
Immuneering Corp Frequently Asked Questions
What is Immuneering Corp(IMRX)'s stock price today?
The current price of IMRX is $5.23. The 52 week high of IMRX is $10.08 and 52 week low is $2.90.
When is next earnings date of Immuneering Corp(IMRX)?
The next earnings date of Immuneering Corp(IMRX) is 2026-08-13 Est..
Does Immuneering Corp(IMRX) pay dividends? If so, how much?
Immuneering Corp(IMRX) does not pay dividend.
Guru Commentaries on NAS:IMRX
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance | 2025-12-12 |
Articles on Immuneering Corp
Headlines
See More- 1
Jun 15, 2026
Immuneering Appoints Andrew Gengos as Chief Financial Officer
Benzinga • 6:30am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers